Recent Studies on HIV Treatments and Patient-Reported Outcomes

Opinion
Video

An expert on HIV discusses recent real-world studies and research on patient-reported outcomes, detailing treatment algorithms under investigation and their reported tolerability.

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following questions:

  • Recent real-world studies and studies on patient-reported outcomes have reported on the overall impact of their therapeutic regimen for HIV. Can you share some more about the results seen in these studies?
    • What treatment algorithms were studied?
    • What was the reported tolerability?

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.